Tesamorelin
| |
Clinical data | |
---|---|
Trade names | Egrifta |
AHFS/Drugs.com | Multum Consumer Information |
MedlinePlus | a611035 |
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ≤4%[1] |
Metabolism | Proteolysis |
Elimination half-life | 26–38 min |
Excretion | Renal/proteolysis |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C221H366N72O67S |
Molar mass | 5135.86 g/mol |
3D model (JSmol) | |
| |
|
Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.[2]
See also
References
- ↑ "Egrifta (tesamorelin for injection) for Subcutaneous Use. U.S. Full Prescribing Information" (PDF). EMD Serono, Inc. Retrieved 9 April 2016.
- ↑ "FDA Application Chemistry Review" (PDF).
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.